MX2022013196A - Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar. - Google Patents

Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar.

Info

Publication number
MX2022013196A
MX2022013196A MX2022013196A MX2022013196A MX2022013196A MX 2022013196 A MX2022013196 A MX 2022013196A MX 2022013196 A MX2022013196 A MX 2022013196A MX 2022013196 A MX2022013196 A MX 2022013196A MX 2022013196 A MX2022013196 A MX 2022013196A
Authority
MX
Mexico
Prior art keywords
pulmonary edema
treating
rock inhibitors
preventing pulmonary
treatment
Prior art date
Application number
MX2022013196A
Other languages
English (en)
Inventor
Irina Kuznetsova
Susanne Herold
John Ziebuhr
Stephan Pleschka
Christin Peteranderl
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2022013196A publication Critical patent/MX2022013196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un inhibidor de ROCK para usarse en el tratamiento o prevención del edema pulmonar asociado con una infección viral. La presente invención se relaciona además con el uso de un sistema de prueba in vitro o la determinación de la efectividad de inhibidores en la prevención o reducción de la localización de sodio-potasio-ATPasa (NKA) apical en células epiteliales pulmonares. También se proporciona un método para detectar moléculas efectivas en la profilaxis y/o tratamiento de un edema pulmonar. Finalmente, la invención se relaciona con un sistema de prueba.
MX2022013196A 2020-04-22 2021-04-22 Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar. MX2022013196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU101746 2020-04-22
PCT/EP2021/060490 WO2021214200A1 (en) 2020-04-22 2021-04-22 Rock inhibitors for use in treating or preventing pulmonary edema

Publications (1)

Publication Number Publication Date
MX2022013196A true MX2022013196A (es) 2022-11-14

Family

ID=70736797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013196A MX2022013196A (es) 2020-04-22 2021-04-22 Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar.

Country Status (10)

Country Link
US (1) US20230172944A1 (es)
EP (1) EP4138846A1 (es)
JP (1) JP2023523730A (es)
KR (1) KR20230004706A (es)
CN (1) CN115666580A (es)
AU (1) AU2021259332A1 (es)
BR (1) BR112022019955A2 (es)
CA (1) CA3173018A1 (es)
MX (1) MX2022013196A (es)
WO (1) WO2021214200A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023199010A1 (en) * 2022-04-13 2023-10-19 University Of Newcastle Upon Tyne Treatment of muscle fibrosis
WO2024145569A2 (en) 2022-12-30 2024-07-04 Avicenna Biosciences, Inc. Azaindole rock inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2011075415A1 (en) * 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
KR20130095263A (ko) 2010-07-27 2013-08-27 인스파이어 파마슈티컬스 인코퍼레이티드 전구약물 형태의 키나아제 저해제 화합물을 사용하여 안질환을 치료하는 방법

Also Published As

Publication number Publication date
KR20230004706A (ko) 2023-01-06
BR112022019955A2 (pt) 2023-02-14
CN115666580A (zh) 2023-01-31
EP4138846A1 (en) 2023-03-01
US20230172944A1 (en) 2023-06-08
CA3173018A1 (en) 2021-10-28
WO2021214200A1 (en) 2021-10-28
JP2023523730A (ja) 2023-06-07
AU2021259332A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2022013196A (es) Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar.
MX2018015516A (es) Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b.
MX2021015675A (es) Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
PH12018502355A1 (en) Enzyme inhibitors
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX366948B (es) Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
BR112023025358A2 (pt) Inibidores de protease como antivirais
WO2022119858A8 (en) Compounds for the treatment of sars
WO2022188898A3 (zh) 化合物盐酸赛庚啶在制备预防或治疗非洲猪瘟药物中的应用
MX2022006490A (es) Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2020009095A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
MX2022000545A (es) Inhibidores de enzimas.
MX2021000404A (es) Oligonucleotidos para modular la expresion de rtel1.
MX2022012576A (es) Inhibidores de axl para terapia antiviral.
MX2020001546A (es) Uso de inhibidores de braf para tratar reacciones cutaneas causadas por el tratamiento con un inhibidor de mek.
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
WO2023192989A3 (en) Phthalazinone compounds as parp7 inhibitors
WO2023114516A3 (en) Cell-permeant inhibitors of viral cysteine proteases
MX2024000406A (es) Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.